Every pharmacy that wants to compound drugs beyond routine reconstitution eventually faces a structural choice: compound under Section 503A of the Federal Food, Drug, and Cosmetic Act, or register as an outsourcing facility under Section 503B. The choice sets which regulator has primary jurisdiction, the state board of pharmacy or the FDA, what standard governs the compounding, and how much volume the pharmacy can lawfully move across state lines. For a pharmacy expanding into GLP-1 class or peptide compounding, getting this structure wrong can mean the difference between compliant operation and unregistered manufacturing exposure.
Patient-Specific Compounding Under Section 503A
Section 503A status, one half of the 503A/503B framework, depends on a valid, patient-specific prescription, or a practitioner's written notation that a compounded version is necessary for an identified patient, before the pharmacy dispenses anything. Compounding must be performed by a licensed pharmacist in a state-licensed pharmacy, or a licensed physician, and the pharmacy generally cannot compound regularly or in significant amounts drugs that are essentially copies of commercially available products. In exchange for staying inside those limits, a 503A pharmacy is exempt from the FDA's manufacturing-grade cGMP framework and from standard new drug approval requirements, and instead follows the USP 797/800 chapters on sterile and hazardous compounding, chapters that state boards of pharmacy enforce through licensing and routine inspection. Interstate shipment is capped at 5 percent of the pharmacy's total prescription orders unless its home state has signed a memorandum of understanding with FDA addressing interstate distribution of compounded drugs.
Anticipatory Compounding and cGMP Under Section 503B
A pharmacy that wants to compound ahead of a prescription, sometimes called anticipatory or office-stock compounding, has to register with FDA as an outsourcing facility under Section 503B. Registration runs annually between October 1 and December 31, requires a unique facility identifier, and carries an annual establishment fee. An outsourcing facility, unlike a 503A pharmacy, may or may not obtain a prescription for an identified patient before compounding, which lets it supply hospitals, clinics, and medical spas with standing stock. That flexibility comes with cGMP compliance under 21 CFR Parts 210 and 211, a manufacturing standard covering environmental monitoring, validated processes, a dedicated quality unit, and formal stability testing, materially heavier than the USP framework a 503A pharmacy follows. FDA inspects outsourcing facilities on a routine, risk-based schedule, typically within two months of initial registration and periodically after that, and the facility must file a report every June and December listing each drug it compounded, along with any adverse events.
Volume, Interstate Reach, and the Practical Decision
The decision usually turns on how the pharmacy actually does business. A pharmacy filling individual prescriptions for a local or regional patient base has little reason to take on cGMP compliance and federal inspection. Staying inside 503A keeps it under familiar state board oversight and preserves the compounding pharmacist-patient-prescriber relationship the exemption is built around. A pharmacy that wants to ship semaglutide, tirzepatide, or peptide preparations to clinics without a prescription for each patient, or that wants to distribute nationally past the 5 percent interstate threshold, cannot do that lawfully as a 503A pharmacy. Pharmacies weighing that question in the semaglutide and peptide space should also see our companion piece on compounding semaglutide after the shortage delisting. The beyond-use date assigned to a compounded preparation is another point where the two tracks diverge: a 503A pharmacy applies USP default limits or its own stability data, while a 503B facility supports its dating with formal stability testing under cGMP.
The prescription-specific limit in Section 503A is the line federal and state regulators use to decide which body of law, and which inspector, has jurisdiction over a given batch of compounded drug.
Why Early Legal Counsel Is Critical
It is critical that pharmacies and compounders consult healthcare regulatory counsel before choosing a structure, not after operations are already underway. A pharmacy that compounds without a patient-specific prescription while operating under 503A, or that markets itself as 503B-compliant without registering, risks FDA warning letters, state board discipline, and enforcement exposure that a properly structured entity would have avoided. Early counsel can evaluate the pharmacy's actual volume and distribution plans, confirm which structure the business model requires, and build the registration and compliance file before a regulator asks for it.
How Health Law Alliance Can Help
Health Law Alliance advises compounding pharmacies and outsourcing facilities on structuring decisions, state board licensing, and FDA registration nationwide. Our bench regularly advises pharmacies weighing a move into anticipatory or office-stock compounding. If your pharmacy is evaluating whether to remain a 503A compounder or register as a 503B outsourcing facility, contact us for a free, confidential consultation.
